Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

294.76 -3.49 (-1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the... 
Via StockStory
Topics Artificial Intelligence
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
How Does Nvidia's Reaching $4 Trillion in Market Cap Impact the S&P 500, Nasdaq-100, and Dow Jones?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
What Does the Market Think About Amgen?
Via Benzinga
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'
Via Benzinga
Topics Economy Government
This House of Representative Just Bought Up To $30K In Amgen Stock
Via Benzinga
1 Top Dividend Growth Stock to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Better Dividend ETF to Buy for Passive Income: SCHD or GCOW
Via The Motley Fool
Topics ETFs Stocks
Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades'
Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets. 
Via Benzinga
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
Via The Motley Fool
Why Amgen Stock Popped by 4% Today
Via The Motley Fool
Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%
The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields. 
Via Benzinga
Topics Stocks
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later. 
Via Benzinga
Amgen’s Cancer Drug Improves Survival In Late-stage Trial
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival as compared to placebo plus chemotherapy in the trial. 
Via Stocktwits
Topics Death
2 Dividend Stocks to Buy on the Dip and Hold Forever
Via The Motley Fool
Topics Government Stocks World Trade
Where Amgen Stands With Analysts
Via Benzinga
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D. 
Via Benzinga
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide. 
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
2 Large-Cap Stocks to Consider Right Now and 1 to Steer Clear Of
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
Topics Economy
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
Members of Congress Are Pouring Millions Into These 7 Surprising Stocks
Via The Motley Fool
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency
The company is progressing with multiple Phase 2 trials for its investigational treatment targeting severe respiratory diseases. 
Via Stocktwits
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.